TripleMed was founded in 2011 by 3 reputed vascular surgeons:  Brom, de Vries and Jacobs, and is located on the Chemelot Campus in Geleen, the Netherlands. TripleMed develops innovative and cost-effective solutions for the treatment of Aortic Aneurysms.
 

The first steps for what is called ‘Balloon-Based EVAR’ were made by de Vries  MD, who had the original idea to develop a soft polymer that can be injected in liquid form into the aneurysm sac around 2 balloons, and subsequently cured to form an in-situ implant.

​

Together with TU Delft a first prototype of the polymer for this idea was developed .

​

After a pilot study in 2018 using this first generation polymer, the polymer was redesigned in 2019 and after extensive in-vitro tests, chemical characterisation studies and full biocompatibility testing acc ISO10993, the pivotal clinical study for treatment of type II Endoleaks was started in 2020. 
 

Based on the data from this clinical study we to expect to obtain our first CE mark under MDR in 2024.

​

​